Amgen TtT - Cascading Pre-Assessment - KSA

Test Your Knowledge: Decision-Making Questions

The following questions are designed to help you and the faculty gauge your current understanding of key concepts related to the clinical content. Responses are confidential and reported in aggregate.

Your overall results will be provided to you on the next page.

1. Which ONE of the following statements regarding the mechanism of action of PCSK9 inhibitors is CORRECT?
2. Which ONE of the following patient groups have randomized control trial (RCT) evidence of cardiovascular outcomes benefits with PSCK9 inhibitors added to maximally tolerated statin therapy?
3. Which ONE of the following statements regarding the efficacy of LDL-C lowering with PCSK9 inhibitors is CORRECT?
4. Which ONE of the following is CORRECT regarding the safety of PCSK9 inhibitors?
5. A 68-year-old man with history of PCI of mid-LAD due to angina in 2012 presents with NSTEMI. At cardiac catheterization he is found to have 90% obstruction of proximal RCA and 50% stenosis of OM1. He had discontinued tobacco use following his previous PCI, but recently resumed 1/2 pack of cigarettes daily. He has well-controlled diabetes with most recent A1c of 6.6%. He has ankle brachial index of 0.8 but is not limited by claudication.

His current medications include aspirin 81 mg daily, clopidogrel 75 mg daily, metoprolol succinate 50 mg daily, lisinopril 5 mg daily, metformin 750 mg twice daily, and atorvastatin 40 g daily.

His most recent lipid panel on atorvastatin 40 mg shows total cholesterol 151 mg/dl ( mmol/L), HDL-C 38 mg/dL ( mmol/L), LDL-C 108 mg/dL ( mmol/L), and triglycerides 125 mg/dL ( mmol/L). The patient has achieved 38% lowering of LDL-C from baseline.

According to the ACC Expert Consensus Decision Pathway on the Role of Non-statin Therapies, which ONE of the following modifications to therapy is indicated?
6. Which ONE of the following statements is CORRECT regarding very low levels of LDL-C achieved with PCSK9 inhibitors added to maximally tolerated statin therapy?

Thank you for your participation.

Your email address is kept confidential and will not be shared.

100% Complete